MENU
JANX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Janux Therapeutics (JANX) Ownership - Who owns Janux Therapeutics?

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer... Show more

Profile

Industry
N/A
Address
10955 Vista Sorrento Parkway
Phone
+1 858 751-4493
Employees
64
Web
https://www.januxrx.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
860.72M
P/E Ratio
N/A
Total Cash
988.99M
Projected Growth
N/A
Total Debt
22.66M
Revenue
10M
Risk (Beta)
4.66
Dividend Yield
N/A
Total Cash/Share
16.44
Total Debt/Equity
N/A
Revenue/Share
0.16 USD as % of share price

Fundamentals

JANX
Capitalization
861M
P/E Ratio
N/A
Risk (Beta)
4.66
Dividend Yield
N/A
Total Cash
989M
Total Cash/Share
16.44
Total Debt
22.7M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.16%
Revenue
10M
ROE
N/A
Book Value
977M
P/B Ratio
0.88
Cash Flow
N/A
Earnings
-1.67
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
60K
Current Ratio
35.86
Current Revenue Per Employee
91743.12
Dividends Per Share - Security
N/A
EBITDA
-142.22M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-11.85
Shares Held By Institutions
2.51B
Shares Outstanding - Current
60.1M
Total Liabilities
48.2M
Total Volume MTD
N/A
Value
1
Gain YTD
-73.272
View a ticker or compare two or three
JANX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. JANX showed earnings on November 06, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
10955 Vista Sorrento Parkway
Phone
+1 858 751-4493
Employees
64
Web
https://www.januxrx.com